Literature DB >> 17127177

Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia.

Dagmar Salber1, Gabriele Stoffels, Dirk Pauleit, Guido Reifenberger, Michael Sabel, Nadim Jon Shah, Kurt Hamacher, Heinz H Coenen, Karl-Josef Langen.   

Abstract

UNLABELLED: Amino acids such as [(11)C-methyl]l-methionine are particularly useful in brain tumor diagnosis, but unspecific uptake (e.g., in cerebral ischemia) has been reported. O-(2-[(18)F]fluoroethyl)-l-tyrosine ([(18)F]FET) shows a clinical potential similar to that of l-methionine (MET) in brain tumor diagnosis but is applicable on a wider clinical scale. The aim of this study was to evaluate the uptake of [(18)F]FET and [(3)H]MET in focal cortical ischemia in rats by dual-tracer autoradiography.
METHODS: Focal cortical ischemia was induced in 25 CDF rats using the photothrombosis (PT) model. At different time points up to 6 weeks after the induction of PT, [(18)F]FET and [(3)H]MET were injected intravenously. Additionally, contrast-enhanced magnetic resonance imaging (MRI) was performed in 10 animals. One hour after tracer injection, brains were cut in coronal sections and evaluated by dual-tracer autoradiography. Lesion-to-brain (L/B) ratios were calculated by dividing the maximal uptake in the lesion by the mean uptake in the brain. An L/B ratio of >2.0 was considered indicative of pathological uptake. Histological slices were stained by cresyl violet and supplemented by immunostainings for glial fibrillary acidic protein (GFAP) and CD68 in selected cases.
RESULTS: A variably increased uptake of both tracers was observed in the PT lesion and its demarcation zone up to 7 days after PT for [(18)F]FET and up to 6 weeks for [(3)H]MET. The cutoff level of 2.0 was exceeded in 12/25 animals for [(18)F]FET and in 18/25 animals for [(3)H]MET. Focally increased tracer uptake matched contrast enhancement in MRI in 3/10 cases for [(18)F]FET and in 5/10 cases for [(3)H]MET. Immunohistochemical staining in lesions with differential uptake of [(18)F]FET and [(3)H]MET revealed that selective uptake of [(18)F]FET was associated with GFAP-positive astrogliosis while selective [(3)H]MET uptake correlated with CD68-positive macrophage infiltration.
CONCLUSIONS: [(18)F]FET, like [(3)H]MET, may exhibit significant uptake in the periphery of cortical infarctions, which has to be considered in the differential diagnosis of unknown brain lesions. There are discrepancies between [(18)F]FET and [(3)H]MET uptake in the area of infarctions that appear to be caused by the preferential uptake of [(18)F]FET in reactive astrocytes versus the preferential uptake of [(3)H]MET in macrophages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127177     DOI: 10.1016/j.nucmedbio.2006.09.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

2.  Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2013-06-07       Impact factor: 12.300

Review 3.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

4.  Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.

Authors:  David O Kamson; Csaba Juhász; Amy Buth; William J Kupsky; Geoffrey R Barger; Pulak K Chakraborty; Otto Muzik; Sandeep Mittal
Journal:  J Neurooncol       Date:  2013-01-09       Impact factor: 4.130

5.  The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

Authors:  Sidsel Højklint Poulsen; Thomas Urup; Kirsten Grunnet; Ib Jarle Christensen; Vibeke Andrée Larsen; Michael Lundemann Jensen; Per Munck Af Rosenschöld; Hans Skovgaard Poulsen; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-23       Impact factor: 9.236

6.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-05       Impact factor: 9.236

7.  Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy.

Authors:  Monica Celli; Paola Caroli; Elena Amadori; Donatella Arpa; Lorena Gurrieri; Giulia Ghigi; Patrizia Cenni; Giovanni Paganelli; Federica Matteucci
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.